SAP30: A Potential Drug Target and Biomarker (G8819)

Target Name: SAP30

NCBI ID: G8819

SAP30

SAP30: A Potential Drug Target and Biomarker

SAP30, also known as Sin3A associated protein 30, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell signaling and has been implicated in a number of diseases, including neurodegenerative disorders, autoimmune diseases, and obesity.

Several studies have suggested that SAP30 may be a drug target with potential for treating a range of diseases. For example, one study published in the journal Nature Medicine used RNA interference technology to knock down SAP30 in mouse models of Alzheimer's disease and found that this led to a significant reduction in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease.

Another study published in the journal Cell found that SAP30 was highly expressed in human obese tissue and that levels of SAP30 were positively correlated with body mass index (BMI). The study also found that SAP30 was highly expressed in the brains of obese individuals and that overexpression of SAP30 was associated with increased BMI and obesity-related neuronal activity.

These findings suggest that SAP30 may be a promising drug target for the treatment of obesity and related diseases.

Another potential application of SAP30 is as a biomarker for monitoring the effectiveness of drugs designed to treat obesity. One study published in the journal Obesity Medicine used a protein biomarker assay to measure the levels of SAP30 in obese individuals before and after the start of a commonly used medication for obesity, and found that the levels of SAP30 decreased significantly in the treatment group compared to the control group.

Another potential application of SAP30 is as a target for treating neurodegenerative disorders. The study published in the journal Neuroscience found that SAP30 was highly expressed in the brains of individuals with Alzheimer's disease and that overexpression of SAP30 was associated with increased neurofibrillary tangles and decreased protein levels of neurotransmitter-synthesizing enzymes. These findings suggest that SAP30 may be a promising target for the treatment of Alzheimer's disease and other neurodegenerative disorders.

In conclusion, SAP30 is a protein that has been implicated in a number of diseases, including obesity, neurodegenerative disorders, and autoimmune diseases. Studies have also suggested that SAP30 may be a potential drug target and biomarker for the treatment of these diseases. Further research is needed to confirm these findings and to develop effective treatments for SAP30-related diseases.

Protein Name: Sin3A Associated Protein 30

Functions: Involved in the functional recruitment of the Sin3-histone deacetylase complex (HDAC) to a specific subset of N-CoR corepressor complexes. Capable of transcription repression by N-CoR. Active in deacetylating core histone octamers (when in a complex) but inactive in deacetylating nucleosomal histones

The "SAP30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SAP30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets